Spero Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Spero Therapeutics Inc SPRO.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of two analysts for the quarter was for a loss of 55 cents per share.

• Revenue fell 36.6% to $5.87 million from a year ago; analysts expected zero.

• Spero Therapeutics Inc's reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $13.87 million.

• Spero Therapeutics Inc shares had fallen by 15.3% this quarter and lost 40.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 107.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Spero Therapeutics Inc is $5.00

This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)